analyzeportfolio
NYSE · Healthcare

TENET HEALTHCARE CORP (THC)

As-reported financials and SEC filings for TENET HEALTHCARE CORP. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About TENET HEALTHCARE CORP

Tenet Healthcare Corporation is a healthcare services company operating 50 acute care and specialty hospitals, 132 outpatient facilities, and a network of employed physicians across eight states. It provides a range of medical services including emergency care, surgery, imaging, and specialized treatments, serving primarily urban and suburban communities. The company also offers revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients through its subsidiary Conifer Health Solutions.

Snapshot

Revenue
$21.31B
Revenue growth (YoY)
3.1%
Net income
$2.37B
Diluted EPS
$15.49
Gross margin
Operating margin
16.5%
Net margin
11.1%
FCF margin
11.9%
ROE
net income / fiscal-year-end equity
P/E
10.3×
trailing when available, otherwise FY EPS
Market cap
$21.56B
Long-term debt / equity
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Tenet Healthcare

  • Revenue grew 3.1% to $21.3B in FY2025, faster than the 0.5% the year before.
  • Operating margin is 16.5% in FY2025, +1.7 pp against 14.7% in FY2021.
  • Most recent quarter Q2 FY2026: revenue $5.6B, up 6.8% from Q2 FY2025.
  • Free cash flow was $2.5B in FY2025, 11.9% of revenue.
  • Net income fell 41.8% to $2.4B in FY2025.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Tenet Healthcare’s fundamentals sit among the 558 Healthcare companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Operating margin16.5%
81st percentile of 399
Net margin11.1%
76th percentile of 418
FCF margin11.9%
71st percentile of 372
Revenue growth (YoY)+3.1%
34th percentile of 538
P/E10.3×
16th percentile of 201
Short interest3.11d
35th percentile of 557

No reported insider purchases (code P) in the last 90 days; 13 insider sales totaling $37.5M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 4 of the superinvestors we track (plus 6 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).

Conviction investors
4
+6 quant / multi-strat
Initiated / added
6
1 new, 5 added
Reduced / exited
4
3 trimmed, 1 exited
Combined position
$705.7M
reported long value
InvestorAs ofPosition valueSharesChange
Citadel AdvisorsquantQ2 2026$330.3M1.8MAdded
AQR Capital ManagementquantQ2 2026$198.3M1.1MReduced
Millennium ManagementquantQ2 2026$86.3M461.5KAdded
Point72 Asset ManagementquantQ2 2026$35.0M187.0KNew
Gotham Asset ManagementQ2 2026$32.6M174.5KAdded
Bridgewater AssociatesQ2 2026$7.9M42.4KAdded
Two Sigma InvestmentsquantQ2 2026$7.4M39.5KReduced
D. E. ShawquantQ2 2026$5.7M30.4KReduced
First Eagle Investment ManagementQ2 2026$1.7M9.1KAdded
Harris Associates (Oakmark)Q2 2026$448,9922.4KHeld

No longer held by: Lone Pine Capital (as of Q2 2026)

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
code P value
Sells (90d)
13
$37.5M
Reported activity
Net selling
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-08-25
filed 2026-08-26
Sutaria SaumyaCEOSell24.9K$274.10$6.8M
2026-08-25
filed 2026-08-26
Sutaria SaumyaCEOSell17.2K$273.34$4.7M
2026-08-25
filed 2026-08-26
Sutaria SaumyaCEOSell7.9K$275.26$2.2M
2026-08-24
filed 2026-08-26
Sutaria SaumyaCEOSell36.7K$278.90$10.2M
2026-08-24
filed 2026-08-26
Sutaria SaumyaCEOSell13.3K$278.17$3.7M
2026-08-24
filed 2026-08-26
HANEY CECIL DDirectorSell1.3K$278.03$361K
2026-08-07
filed 2026-08-10
Romo TammyDirectorSell2.5K$260.83$652K
2026-08-06
filed 2026-08-10
Romo TammyDirectorSell4.9K$264.15$1.3M
2026-08-05
filed 2026-08-07
Blunt RoyDirectorSell600$262.68$158K
2026-07-29
filed 2026-07-31
Foo Lisa YEVP, Chief Operating OfficerSell10.0K$258.03$2.6M
2026-07-27
filed 2026-07-28
Arbour Paola MEVP, Chief Information OfficerSell10.9K$243.90$2.7M
2026-07-27
filed 2026-07-28
BIERMAN JAMES LDirectorSell5.0K$244.96$1.2M

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
2.5M
settled 2026-08-14
Change vs prior
-21.2%
vs previous settlement
Days to cover
3.11
at avg daily volume
Avg daily volume
812.1K
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-142.5M-21.2%3.11
2026-07-313.2M+7.5%2.01
2026-07-153.0M-20.3%2.24
2026-06-303.7M-7.9%2.85
2026-06-154.1M+23.9%2.67
2026-05-293.3M+31.1%2.30
2026-05-152.5M+14.4%1.53
2026-04-302.2M-8.9%1.33

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$21.31B$20.68B$20.56B$19.17B$19.48B
Gross profit
Operating income$3.51B$5.96B$2.51B$2.33B$2.87B
Net income$2.37B$4.06B$1.31B$1.00B$1.48B
Diluted EPS$15.49$32.70$5.71$3.79$8.42

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$3.54B$2.05B$2.37B$1.08B$1.57B
Capital expenditure$1.01B$931.0M$751.0M$762.0M$658.0M
Free cash flow$2.53B$1.12B$1.62B$321.0M$910.0M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q2 FY2026$5.63B6.8%$1.04B$9.84
Q1 FY2026$5.37B2.8%$906.0M$8.01
Q4 FY2025$5.53B8.9%$4.21
Q3 FY2025$5.29B3.2%$579.0M$3.86
Q2 FY2025$5.27B3.2%$522.0M$3.14
Q1 FY2025$5.22B-2.7%$622.0M$4.27
Q4 FY2024$5.07B-6.0%$3.43
Q3 FY2024$5.13B1.2%$681.0M$4.89

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNYSE
SectorHealthcare
SIC industryServices-General Medical & Surgical Hospitals, NEC
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ2 FY2026 (ended June 30, 2026)
Oldest indexed filing2014
SEC CIK70318

Selected SEC filings

10-Q2026-07-29
View on EDGAR →
10-Q2026-04-30
View on EDGAR →
8-K2026-07-23
View on EDGAR →
8-K2026-05-29
View on EDGAR →
8-K2026-04-30
View on EDGAR →
8-K2026-04-10
View on EDGAR →

Largest Healthcare peers

All Healthcare companies →

Monitor THC

Get an alert when Tenet Healthcare files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor THC free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.